Member Info for EmeraldCarrots

Let's face it, the sp is so -F*U-C'k_i-N g low it is beyond belief.

let's face it, the sp is so ******* i n g low it is beyond belief.

Happy talking, happy talk.........

TwoGood2Die. So you work for LSE, do you not? Every post "no opinion", argue creating more posts that LSE can market as in "we get x posts a day". AND the reason you never get banned no matter what lies you throw in to get a reaction??

"Interesting today. Volume very thin this morning. MM’s drop price and buyers come in. Some Shorts exiting their positions? Or wishful thinking?".

===================

Shorts positions reported @ 3.71% I see.

https://www.lse.co.uk/ShareChat.html?ShareTicker=ITM&share=Itm-Power

Ennismore Fund Management Limited 0.80% 0.09% 1 May 2024

Helikon Investments Limited 2.91% 0.23% 13 Feb 2024

Total 3.71%

Looking back at your posts it looks like nothing. You seem to comment about other peoples posts. Mostly negative. Are you lonely or something? I have never seem you post refering to an artical of interest in AGL.... never. As for TwpGood2Die, who is a proven liar on here, yet never gets banned by the moderator, if there is one, on here. He/she posts time and time again just to annoy me, but the moderator on here does little, if anything. This bb seems to be a free for all. Policy being delete posts that are complained about, but never ban anyone. Not good.

Interesting.

Interesting:-

https://shorttracker.co.uk/company/GB00B0H2K534/

Range_Rover1990.

Good post based backed up with a professional article. Unlike some posts on here that that are based on what a poster has assumed, based on well, what they have assumed. The following are the main services agreements. People are forgetting this is only part of what Angle do. Selling the Parsortix machine ($50,000 each plus) and consumables is the backbone of the Company for the moment. Likely it will be overtaken by the services side in due course.

2-1-2024.

https://www.lse.co.uk/rns/AGL/contract-announcement-with-eisai-inc-49aplx5us0gzg6h.html

"Pilot study for ANGLE's Portrait HER2 assay in Phase II study of HER2 targeting antibody-drug conjugate, BB-1701"

"Under the agreement, in a pilot study worth US $250,000 to ANGLE, ANGLE will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701. Success in the pilot study offers the potential for multiple large scale follow-up studies"

I believe this is based on the Services HER2 assay Angle now offer to use in other cancer drug trials on their WEB site TO OTHER COMPANIES. Note Angle own the assays they develop.

There are over 3000 Breast cancer drug trials in the World now. Massive potential here already.

24-4-2024.

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-astrazeneca-edeymgqdtcshqde.html

"ANGLE signs agreement to tailor existing Parsortix-based DNA damage response assay for use in pharmaceutical R&D". "Under the agreement, ANGLE will develop a novel methodology for CTC micronuclei detection based on its existing pKAP1 CTC-based DDR assay, which measures expression of a key protein in the DNA damage response. Assay development will take place in ANGLE's laboratories in Guildford, UK, and follows the Company's development and launch of two highly sensitive and specific DDR assays in 2023. The 6-month development phase is worth an initial £150,000 to ANGLE.".

3-5-2024.

https://www.lse.co.uk/rns/AGL/new-commercial-agreement-with-large-pharma-gvzk9wgh1la0ljx.html

"ANGLE commissioned to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies". "Under the terms of this agreement, worth £550,000 to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025. A successful development phase will demonstrate the importance of the Parsortix system in assessing the efficacy of prostate cancer therapeutics and offers the potential for long-term, ongoing business for the Company supporting clinical studies.".

All IMHO.

Diving on open..................

Very well. Now worth 1m shares @ 2.1p = £20,500.00. So a loss of £10,500 in less than 4 weeks. Ouch. Maybe bounce tomorrow.

Dow only down 50 or so. They did get off to a big dip of course. Very annoying. If they stay like this expect a bounce 1st thing. USA markets GRRRRRRRRR!

Dow only down 50 or so. They did get off to a big dip of course. Very annoying. If they stay like this expect a bounce 1st thing.

Researcher1.

Angle was/is not a big enough Company to fund the assays. Anyway, at the end of the day the Companies doing the cancer drug trials are the ones who know what they want to monitor in the cancer cells. Any cancer drug is designed to do x to a cancer cell. That is obvious. So, one needs an assay to test that x in the cancer cells before, during and after treatment. Then, obviously, you can see what effect (if any) your expensive drug has on the cancer cells. It is so totally and utterly obvious to anyone. Angle have the parsortix machine to catch live intact cancer cells. It is up to the big Pharma Co's TO INVEST in the assays (tests) to find out (within days) what effect their drug is having. It is totally incredible more Pharma Plc's are not doing business with Angle Plc........... yet.

All IMHO

Term this may pay huge dividends (excuse the pun!). Once the other 100's of Pharma Plc's (other than Eisai and Astrazeneca) want to get on board to find out what the circulating tumour cells can reveal about a persons cancer I'm sure he will make the ones who are not playing ball now both wait and pay more. Hope he does. It is incredibly frustrating more of the most massive Pharma Plc's are not on board. IMHO they are foolish.

All IMHO.

Researcher1

"I agree with much that you say Emerald - I'm just not going to touch a Newland company with a bargepole. I especially agree that he is responsible for holding up cancer research. He's a total disgrace.".

============================

I did not say that. It is the Pharma Co's (other than Eisai and Astra) that are incrediby slow to appreciate what analysing the circulating tumour cells can reveal about a persons cancer that are the problem. I think they were playing the "we'll wait for some other Pharma Co. to invest rather than invest themselves" and now this angle (excuse the pun) of knowledge has been put back what...... a year or more. It is the big Pharma Co's who have not invested in other assays etc.. to push research and knowlege further. They are the ones who are a total disgrace if you ask me. They don't have to pay Angle to do the assays, they could do their own ones. But no............ we won't spend we'll wait for someone else to do it...... Total disgrace. At least Astrazeneca and Eisai have done their bit. We wait for the rest to get thie fingers out......

All IMHO.

German investment bank Berenberg!! Published 09:42 11 Sep 2024 BST. Less than 1hr ago.

Https://www.proactiveinvestors.co.uk/companies/news/1056006/angle-technology-sets-the-gold-standard-in-cancer-diagnostics-investment-bank-1056006.html

Simply the lack of positive RNS's in the last 3 months. Angle's sales side, at least as far as the selling services to big Pharma Plc's along the lines of the Eisai and AstraZeneca contracts has simply not, so far, performed. If it had, we would have seen more RNS's. To be honest I am extremely surprised we have still not got more contracts of similar nature. We need to bear in mind of course that Angle Plc would not need more than one or two to zoom the sp North. I am pleased that the WEB site now shows the HER2 assay test as a service to the cancer drug trial industry. This must be the assay developed for Eisai's original use which Angle now own (see the RNS from 2nd Jan). I strongly believe any company in the world who carries out a Breast cancer drug trial should be falling over themselves to buy this service. Unfortunately, this industry is incredibly slow to make decisions. It seems to me sometimes several months if not more than a year are wasted by these huge Plc's. I find it quite disturbing that cancer research is being slowed up in this way. We need to bear in mind sales of the Parsortix machines and the consumables you need to run it will not be reported until the interims, so no RNS's expected on that front. Angle only did a placing @ 15p a share in June so I have no concerns about their cash situation until at least July 2025. Keep the faith. They do have the tech!! The large Pharma Co's are S L O W L Y starting to realise Angle really do have something. It’s almost scandalous more of them are not on Angle's books. This will change.

All IMHO.

Spreading negative thoughts about AGL, over 4 months before AGL's year end of 31/12/24!!! What a nice person you are!

From your post:-

"they never forecast where the £6.45m was coming from, but whatever *** packet they wrote the calculation on, I very much doubt they were on track for by h1.".". You said this 4 months before AGL's year end.......................................LOL!

Today is 11th September.

The terms of payment in any business deal are negotiable. Payment "up front" happens, ever run a business like I have?

Angle are NOW offering the HER2 to Companies doing Breast cancer drug trials, there are over 3,000 taking place in the World right now. Yes, THREE THOUSAND. Angle only need to get what.... 6 orders in? Not even that. One or 2 would PROBABLY send the sp way over 20p and you know it. Eisai are already on board. Astrazeneca have placed orders regarding examining the circulating tumour cell (CTC) proteins in other ways too. The sp is poised to ROCKET and if you can't see that then I think you need your head examined.

From the Angle WEB page:-

Benefits for your clinical research:

The presence of HER2-positive CTCs in patients with initially HER2-negative primary tumours has significant potential implications.

Association with poor prognosis.

Potential prognostic marker for longitudinal monitoring.

Optimised patient selection, through fast and accurate indicators of therapeutic performance.

Early competitive advantage by understanding therapeutic response sooner!!!!

Reduced trial size, costs, and time !!!!

Just a matter of time until the sp ROCKETS!!!!!!!!!!!!!!

Https://angleplc.com/laboratory-services/her2/

I have recently bought more AGL sub 12p.

All IMHO.

Https://angleplc.com/laboratory-services/her2/

From the WEB page:-

Benefits for your clinical research:

The presence of HER2-positive CTCs in patients with initially HER2-negative primary tumours has significant potential implications.

Association with poor prognosis.

Potential prognostic marker for longitudinal monitoring.

Optimised patient selection, through fast and accurate indicators of therapeutic performance.

Early competitive advantage by understanding therapeutic response sooner!!!!

Reduced trial size, costs and time !!!!

Just a matter of time until the sp ROCKETS!!!!!!!!!!!!!!

All IMHO.